14 results about "Nicotinic Acids" patented technology

The present invention relates to amino acid salts of nicotinic acid ribosides and compositions thereof of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in NAD+:wherein M1, R1, R2, and R3 are as described herein.

This invention provides a chemical mechanical polishing (CMP) slurry and its application. The CMP slurry comprises: a catalyst, a stabilizer, an oxidant, a pH adjuster, abrasive particles, a corrosion inhibitor, and water. The corrosion inhibitor is a nitrogen-containing heterocyclic carboxylic acid compound, wherein the nitrogen-containing heterocyclic carboxylic acid compound includes at least one selected from nicotinic acid, isonicotinic acid, pyridinecarboxylic acid, imidazocarboxylic acid, pyrazolecarboxylic acid, 3-pyridineacetic acid, 3-pyridinepropionic acid, 3-methyl-2-pyridinecarboxylic acid, and L-piperidine acid. The CMP slurry provided by this invention can simultaneously polish tungsten and silicon oxide, and can also control the polishing rate of silicon oxide while inhibiting tungsten corrosion, thus making it suitable for different application scenarios. In addition, the CMP slurry has good stability and can maintain its performance even after long-term standing.

The present application relates to the technical field of organic synthesis, and particularly relates to an asymmetric preparation method of nicotine and derivatives thereof.The method of the present application takes nicotinic acid ester or substituted nicotinic acid ester and N-methyl pyrrolidone as raw materials, obtains a hydrochloride intermediate through condensation and ring-opening decarboxylation, then obtains chiral amino alcohol through asymmetric reduction, and finally obtains nicotine and analogs thereof through intramolecular ring-closing reaction.The preparation method disclosed by the present application has the advantages that raw materials are easy to obtain, operation is convenient, the process is short, the obtained product nicotine and derivatives thereof are easy to purify, and the optical purity is high.

The application discloses an aspartate ligase mutant and application thereof in production of nicotinamide, and belongs to the technical field of enzyme engineering. The aspartate ligase mutant is obtained by mutation on the basis of wild-type aspartate ligase shown in SEQ ID NO. 5, and at least includes the 104th site. The aspartate ligase mutant has higher catalytic activity in catalyzing synthesis of nicotinamide from nicotinic acid, and can significantly improve the production efficiency of nicotinamide. Coupling of the aspartate ligase mutant with polyphosphate phosphate transferase can also realize ATP cycle regeneration, reduce the addition amount of ATP, and further greatly reduce the preparation cost of nicotinamide. Therefore, the mutant is suitable for industrial production, and has good application prospect.

The application relates to the technical field of microbial culture medium, and discloses a chemical component limited culture medium for supporting growth of bifidobacterium and application thereof. The CDM comprises a carbon source, salts, amino acids, vitamins and water; the carbon source is selected from at least one of glucose, fructose, lactose, maltose and galactooligosaccharide, the salts comprise sodium acetate, potassium hydrogen phosphate, ammonium acetate, magnesium sulfate heptahydrate, ferrous sulfate heptahydrate, sodium chloride and manganese sulfate monohydrate, the amino acids comprise alanine, cystine, cysteine, tryptophan and asparagine, and the vitamins comprise pyridoxine hydrochloride, nicotinic acid, calcium pantothenate, thiamine hydrochloride, riboflavin, p-aminobenzoic acid, folic acid and biotin. The CDM of the application is a liquid culture medium, only comprises 21 definite components, is simple in components, convenient in preparation, and is high in universality, and can effectively support growth of bifidobacterium.

This invention discloses a glutamine transaminase mutant and its applications, belonging to the field of bioengineering technology. The glutamine transaminase mutant of this invention is obtained by mutation based on the wild-type glutamine transaminase shown in SEQ ID NO.1. This invention modifies the substrate spectrum of the glutamine transaminase derived from Streptomyces, and the obtained glutamine transaminase mutant can catalyze the synthesis of nicotinamide from nicotinic acid. Combined with the synthesis method of this invention, an extremely high nicotinic acid conversion rate can be achieved, significantly increasing the yield of the product nicotinamide. Therefore, the glutamine transaminase mutant of this invention has good prospects for industrial application in nicotinamide synthesis.

To provide cosmetics that offer both effective improvement of skin blemishes and wrinkles and a pleasant user experience. [Solution] (A) Glycine derivative or salt thereof, (B) Nicotinic acid or derivative thereof, (C) an alkyl-modified carboxyvinyl polymer, (D) an oil, and (E) water, comprising an oil-in-water emulsion cosmetic. This cosmetic contains 0.3 to 5% by mass of component (A) based on the total amount of the cosmetic.

The application belongs to the technical field of nutrition, and particularly relates to a special medical composition for pregnant women and a preparation method and application thereof. The composition comprises the following components: DHA in the form of phospholipid, active folic acid, vitamin B1, vitamin B2, vitamin B6, vitamin B1, vitamin A, vitamin D, vitamin C, nicotinic acid, pantothenic acid, calcium element, iron element and zinc element. The calcium element is derived from calcium carbonate, the iron element is derived from ferrous gluconate, and the zinc element is derived from zinc sulfate. The composition provided by the application can act on the key window before pregnancy and in the early pregnancy period, and actively perform nutrition storage and metabolism regulation by using high-bioavailability key nutrients such as DHA in the form of phospholipid and active folic acid, and combining specific proportions of B vitamins, vitamin C, vitamin A, vitamin D and minerals.

This invention discloses the cytotoxic analog N'-biphenylnicotinamide, represented by structural formula I, its pesticide-acceptable salts and pharmaceutical compositions, and its application in the preparation of agricultural fungicides; and the preparation of N'-biphenylnicotinamide derivatives by substituted nicotinic acid and substituted biphenylhydrazine under the action of a condensing agent. Wherein, X is selected from: hydrogen, fluorine, chlorine, bromine, iodine, trifluoromethyl, methyl, or ethyl; Y... 1 Selected from: hydrogen, fluorine, chlorine, bromine, iodine, methyl or ethyl; Y 2 Selected from: hydrogen, fluorine, chlorine, bromine, iodine, methyl or ethyl; Y 3 Selected from: hydrogen, fluorine, chlorine, bromine, iodine, methyl or ethyl; Y 4 Selected from: hydrogen, fluorine, chlorine, bromine, iodine, methyl, ethyl, methoxy, or trifluoromethyl; Y 5 Selected from: hydrogen, fluorine, chlorine, bromine, iodine, methyl or ethyl; Y 6 Selected from: hydrogen, fluorine, chlorine, bromine, iodine, methyl or ethyl.

This invention discloses an enzyme-catalyzed method for the synthesis of nicotinic tripeptide-1 and its derivatives, belonging to the field of biocatalysis and peptide synthesis technology. The method uses nicotinic acid or its active ester and tripeptide-1 (GHK) or its salt as substrates, and carries out an amidation reaction in a non-aqueous phase or an organic solvent system containing a small amount of water, catalyzed by a protease or lipase, to efficiently and selectively synthesize nicotinic tripeptide-1. This method features mild reaction conditions (20-60°C), requires no protection or deprotection of amino acid side chains, has few side reactions, produces high-purity products, is environmentally friendly, and the enzyme can be recycled, significantly reducing production costs and waste emissions, making it suitable for industrial production. The obtained product has broad application prospects in the fields of cosmetics, health products, and pharmaceuticals.

[Problem] An objective of the present invention is to provide a water-in-oil emulsion sunscreen cosmetic that allows a medicinal agent to be blended into the internal phase, while having high ultraviolet protection power. [Solution] The sunscreen cosmetic of the present invention is characterized by comprising: (A) an ultraviolet absorbing agent; (B) a medicinal agent selected from the group consisting of L-ascorbic acid and derivatives thereof, tranexamic acid and derivatives thereof, alkoxysalicylic acid and derivatives thereof, glycyrrhizinic acid and derivatives thereof, and nicotinic acid and derivatives thereof; (C) a water-soluble thickener that is not sugar-derived; and (D) water.

The present application relates to the technical field of scale inhibition, and proposes a gasifier ash water scale inhibitor and a preparation method thereof.The gasifier ash water scale inhibitor comprises the following components in parts by weight: polycarboxylic acid 22-35 parts, polysulfonate 21-28 parts, phosphate 5-12 parts, phosphonic acid 8-12 parts, azole 3-9 parts, auxiliary agent 22-30 parts, alcohol 15-25 parts, suspending agent 25-30 parts, and water 200-220 parts; the auxiliary agent comprises 2-pyridine carboxylic acid and 6-aminonicotinic acid.Through the above technical solution, the problem of poor scale inhibition performance of the scale inhibitor in the related art is solved.

The present invention aims to provide a liquid oral composition that has an astringent sensation, effectively suppresses discoloration over time, and improves the sour taste during use. [Solution] The present invention relates to a liquid oral composition comprising (A) component: pyridoxine or a salt thereof, (B) component: glycerin, and (C) component: at least one selected from the group consisting of sorbitol, propylene glycol, and polyethylene glycol, wherein the ratio of the content (mass%) of component (B) to the content (mass%) of component (C) is less than 1, more preferably (D) component: a predetermined sweetener, and even more preferably (E) component: at least one selected from the group consisting of tocopherol acetate and tocopherol nicotinate.